Cost-effectiveness of long-chain omega-3 supplementation for the secondary prevention of cardiovascular disease in the United States
Abstract
OBJECTIVE
A variety of EPA and DHA omega-3 dietary supplements of varying dosage and pricing are available in the US and commonly used for secondary cardiovascular prevention. While these interventions' efficacy has been studied, their cost-effectiveness remains unknown. The goal of this article is to assess whether omega-3 dietary supplements are cost-effective for secondary cardiovascular prevention in adults in the USA. Our analysis explicitly incorporates a reported higher risk of atrial fibrillation associated with omega-3 supplementation.
METHODS
This economic evaluation used a Markov model over a ten-year horizon with health states defined by cardiovascular disease status. Effectiveness was measured by quality-adjusted life-years (QALYs) gained and costs were calculated from a US healthcare system perspective, estimated in 2023 US dollars. Data were obtained from the published literature. Deterministic and probabilistic sensitivity analyses were conducted to estimate the influence of parameter uncertainties on the resulting cost-effectiveness ratios. Scenarios including low (300 mg/day), medium (1000 mg/day) and high (2500 mg/day) supplementation dosages of EPA and DHA omega-3s were considered. Average (ACERs) and incremental cost-effectiveness ratios (ICERs) in US$/QALY are presented.
RESULTS
At a willingness-to-pay (WTP) threshold of $50,000/QALY, 1000 mg/day is the most cost-effective dose (ICER of $ 25,024). At a WTP of $100,000, 2500 mg/day (ICER of $57,981) is…
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.